UCSF researchers have found a treatment for HIV that shows potential as a long-term solution for the chronic disease that, up ...

People infected with HIV must take antiretroviral drugs for life. But engineered antibodies appeared to suppress the virus ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Pill burden decreases and antiretroviral regimens simplify for many of the participants who start lenacapavir.

Adding lenacapavir to HIV treatment effectively simplified complicated regimens while lowering or maintaining virological ...

Antiretroviral drugs that prevent HIV and keep it in check have been transformative, but a cure has been a long-sought goal.

Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

HIV treatment has significantly evolved over the past 30 years, transforming HIV from a fatal disease to a manageable chronic ...

Viral suppression is one of the major goals of the Centers for Disease Control and Prevention (CDC) Ending the HIV Epidemic in the US (EHE) initiative. 1 Viral suppression is defined in this context ...

– Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis of Regulatory Submissions – Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 ...